Replies to post #825542 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Technicians always believe after a big advance they'll be a 30% to 50% retrenchment of the advance. That said, our advance could continue moving up until approval. The peak established there could be where we retrench from. With $.20 considered the base, if we achieve anything above $3 it hardly matters whether you look at $.20 as the base, or zero as the percentage doesn't change that much. If we reach $3, retrenching to $2 or near $1.50 would be expected by the technicians. That would establish a new base for the next advance.

The question for investors is whether getting out at the high, and back in after retrenchment makes sense when considering tax consequences. It becomes much clearer if the peak's at $10 and retrenchment is anticipated to near $5.

To me, $5 represents about an $8 billion market cap, I believe that more than UK approval alone is needed to trade stabile at that price. I believe more will be coming, I'm uncertain how quickly.

Regardless of where we are post approval, I believe by the end of the year we'll see $5 to $10, or more. There will be a great deal of news between approval and then.

Gary

[flipper44]

20% you say? Hmm.

[DJPele]

I feel as if we are seeing history repeat itself....yet again. With how this has played out in the past, this is what I expect:

1.) The PPS may see a quick rally in the morning, followed by a short sell-off.

2.) Sideways trading will occur, until late morning/early afternoon.

3.) Early-Mid afternoon is where the floor drops. EOD we will sit in the negative at around $0.23 or so.

With the onset of dilution and a very, VERY delayed MHRA decision, we are struggling to capitalize on these rallies and exit this depression. We NEED a positive MHRA approval decision, along with subsequent positive PR's/Announcements to climb out of this trench.